Market Overview

UPDATE: Bank of America Downgrades Abaxis on Growth Concerns, Valuation

Related ABAX
Is Abaxis Worth Adding To Your Investment Portfolio?
Chimerix, Inc. (CMRX) in Focus: Stock Up 5.6%

In a report published Friday, Bank of America analyst Erin E. Wilson downgraded the rating on Abaxis (NASDAQ: ABAX) from Neutral to Underperform, and lowered the price target from $36.00 to $35.00.

In the report, Bank of America noted, “ABAX's shares have increased 11% off of a low in December (vs. +4% S&P 500), despite a string of disappointing earnings reports, recent management turnover, and less traction from its expanded MWI Veterinary Supply distribution relationship. With the stock at a higher value, despite limited clarity on its future growth, we are lowering our rating to Underperform (from Neutral). We are also cutting our 2015E EPS to $0.90 (from $0.95) to reflect a lower contribution from MWI and an evolving competitive landscape that appears increasingly unfavorable for ABAX. Our PO moves to $35 (from $36).”

Abaxis closed on Thursday at $39.15.

Latest Ratings for ABAX

DateFirmActionFromTo
Sep 2014Canaccord GenuityUpgradesHoldBuy
Jul 2014Canaccord GenuityMaintainsHold
Feb 2014Bank of AmericaDowngradesNeutralUnderperform

View More Analyst Ratings for ABAX
View the Latest Analyst Ratings

Posted-In: Bank of America Erin E. WilsonAnalyst Color Downgrades Analyst Ratings

 

Related Articles (ABAX)

Around the Web, We're Loving...

Get Benzinga's Newsletters